News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only
Fish oil lipid emulsion shows promise in adults with IFALD
14 Oct 2024
Disease Link 3 oil injectable lipid emulsions (ILE) in adults with cholestatic Disease Link 4 -associated Disease Link 5 disease Disease Link 6 effective and is safe, with no essential fatty acid (EFA) deficiencies observed up to 4 years of use, suggests a study.
Fish oil lipid emulsion shows promise in adults with IFALD
14 Oct 2024
MARIPOSA update: Amivantamab-lazertinib bests osimertinib for EGFRm NSCLC at 3 years
14 Oct 2024
byAudrey Abella
The updated efficacy analysis of the phase III MARIPOSA trial continues to favour amivantamab plus lazertinib over osimertinib for first-line (1L) treatment of patients with EGFR-mutant (EGFRm) advanced non-small cell lung cancer (NSCLC).
